CXCL16 and breast cancer: ST analysis of brain metastases from breast cancer (Fig. 3G) and liver metastases from CRC (Fig. 3L) suggested that the CXCL16-CXCR6 signaling axis did not promote CD8+ T-cell activation or even exerted a suppressive effect (Fig. 3H, M), while the ANXA1-FPR3 signaling axis may enhance macrophage activity (Fig. 3I, N).